Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection.

Lawitz E, Poordad F, Anderson LJ, Vesay M, Kelly MM, Liu H, Gao W, Fernsler D, Asante-Appiah E, Robertson MN, Hanna GJ, Barr E, Butterton J, Kowdley KV, Hassanein T, Sahota A, Gordon SC, Yeh WW.

J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079. [Epub ahead of print]

PMID:
30739366
2.

Discovery of novel pan-genotypic HCV NS5A inhibitors containing a novel tetracyclic core.

Yu W, Hu B, Zhong B, Hao J, Lei Z, Agrawal S, Rokosz L, Liu R, Chen S, Asante-Appiah E, Kozlowski JA.

Bioorg Med Chem Lett. 2019 Mar 1;29(5):700-706. doi: 10.1016/j.bmcl.2019.01.031. Epub 2019 Jan 25.

PMID:
30711390
3.

Efficacy and safety of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1, 4, or 6 infection from the Asia-Pacific region and Russia: Final results from the randomized C-CORAL study.

Wei L, Jia JD, Wang FS, Niu JQ, Zhao XM, Mu S, Liang LW, Wang Z, Hwang P, Robertson MN, Ingravallo P, Asante-Appiah E, Wei B, Evans B, Hanna GJ, Talwani R, Duan ZP, Zhdanov K, Cheng PN, Tanwandee T, Nguyen VK, Heo J, Isakov V, George J; C-CORAL Investigators.

J Gastroenterol Hepatol. 2019 Jan;34(1):12-21. doi: 10.1111/jgh.14509. Epub 2018 Dec 9.

PMID:
30311701
4.

In Vitro Antiviral Profile of Ruzasvir, a Potent and Pangenotype Inhibitor of Hepatitis C Virus NS5A.

Asante-Appiah E, Liu R, Curry S, McMonagle P, Agrawal S, Carr D, Rokosz L, Lahser F, Bystol K, Chase R, Black S, Ferrari E, Ingravallo P, Tong L, Yu W, Kozlowski J.

Antimicrob Agents Chemother. 2018 Oct 24;62(11). pii: e01280-18. doi: 10.1128/AAC.01280-18. Print 2018 Nov.

PMID:
30150466
5.

Evolutionary pathways to NS5A inhibitor resistance in genotype 1 hepatitis C virus.

Zhou S, Williford SE, McGivern DR, Burch CL, Hu F, Benzine T, Ingravallo P, Asante-Appiah E, Howe AYM, Swanstrom R, Lemon SM.

Antiviral Res. 2018 Oct;158:45-51. doi: 10.1016/j.antiviral.2018.07.024. Epub 2018 Aug 3.

PMID:
30081054
6.

Interim analysis of a 3-year follow-up study of NS5A and NS3 resistance-associated substitutions after treatment with grazoprevir-containing regimens in participants with chronic HCV infection.

Lahser F, Galloway A, Hwang P, Palcza J, Brunhofer J, Wahl J, Robertson M, Barr E, Black T, Asante-Appiah E, Haber B.

Antivir Ther. 2018;23(7):593-603. doi: 10.3851/IMP3253. Epub 2018 Jul 24.

PMID:
30038064
7.

Discovery of MK-6169, a Potent Pan-Genotype Hepatitis C Virus NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Substitutions.

Yu W, Tong L, Selyutin O, Chen L, Hu B, Zhong B, Hao J, Ji T, Zan S, Yin J, Ruck RT, Curry S, McMonagle P, Agrawal S, Rokosz L, Carr D, Ingravallo P, Bystol K, Lahser F, Liu R, Chen S, Feng KI, Cartwright M, Asante-Appiah E, Kozlowski JA.

J Med Chem. 2018 May 10;61(9):3984-4003. doi: 10.1021/acs.jmedchem.7b01927. Epub 2018 May 1.

PMID:
29681153
8.

MK-8325: A silyl proline-containing NS5A inhibitor with pan-genotype activity for treatment of HCV.

Nair AG, Zeng Q, Selyutin O, Rosenblum SB, Jiang Y, Yang DY, Keertikar K, Zhou G, Dwyer M, Kim SH, Shankar B, Yu W, Tong L, Chen L, Mazzola R, Caldwell J, Tang H, Agrawal S, Liu R, Kong R, Ingravallo P, Xia E, Zhai Y, Nomeir A, Asante-Appiah E, Kozlowski JA.

Bioorg Med Chem Lett. 2018 Jun 1;28(10):1954-1957. doi: 10.1016/j.bmcl.2018.03.049. Epub 2018 Mar 20.

PMID:
29653894
9.

Elbasvir/grazoprevir and sofosbuvir for hepatitis C virus genotype 3 infection with compensated cirrhosis: A randomized trial.

Foster GR, Agarwal K, Cramp ME, Moreea S, Barclay S, Collier J, Brown AS, Ryder SD, Ustianowski A, Forton DM, Fox R, Gordon F, Rosenberg WM, Mutimer DJ, Du J, Gilbert CL, Asante-Appiah E, Wahl J, Robertson MN, Barr E, Haber B.

Hepatology. 2018 Jun;67(6):2113-2126. doi: 10.1002/hep.29852. Epub 2018 Apr 19.

PMID:
29473975
10.

Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: A pooled analysis.

Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Talwani R, Serfaty L.

Liver Int. 2018 Sep;38(9):1583-1591. doi: 10.1111/liv.13727. Epub 2018 Mar 31.

PMID:
29461687
11.

Identification of novel bifunctional HIV-1 reverse transcriptase inhibitors.

Lai MT, Tawa P, Auger A, Wang D, Su HP, Yan Y, Hazuda DJ, Miller MD, Asante-Appiah E, Melnyk RA.

J Antimicrob Chemother. 2018 Jan 1;73(1):109-117. doi: 10.1093/jac/dkx332.

PMID:
29029095
12.

Preclinical and clinical properties of elbasvir (ERELSA® Tablets 50 mg) and Grazoprevir (GRAZYNA® Tablets 50 mg), novel therapeutic agents for hepatitis C.

Kinoshita K, Iwasa T, Asante-Appiah E, Nakamura K.

Nihon Yakurigaku Zasshi. 2017;150(1):41-53. doi: 10.1254/fpj.150.41. Japanese. No abstract available.

PMID:
28690275
13.

Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naïve, noncirrhotic HCV genotype 3-infected patients.

Gane E, Nahass R, Luketic V, Asante-Appiah E, Hwang P, Robertson M, Wahl J, Barr E, Haber B.

J Viral Hepat. 2017 Oct;24(10):895-899. doi: 10.1111/jvh.12719. Epub 2017 Jun 23.

PMID:
28470815
14.

Antiviral Activity and Resistance Analysis of NS3/4A Protease Inhibitor Grazoprevir and NS5A Inhibitor Elbasvir in Hepatitis C Virus GT4 Replicons.

Asante-Appiah E, Curry S, McMonagle P, Ingravallo P, Chase R, Nickle D, Qiu P, Howe A, Lahser FC.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e00363-17. doi: 10.1128/AAC.00363-17. Print 2017 Jul.

15.

Unraveling the structural basis of grazoprevir potency against clinically relevant substitutions in hepatitis C virus NS3/4A protease from genotype 1a.

Guo Z, Black S, Hu Y, McMonagle P, Ingravallo P, Chase R, Curry S, Asante-Appiah E.

J Biol Chem. 2017 Apr 14;292(15):6202-6212. doi: 10.1074/jbc.M116.772996. Epub 2017 Feb 21.

16.

Discovery of Ruzasvir (MK-8408): A Potent, Pan-Genotype HCV NS5A Inhibitor with Optimized Activity against Common Resistance-Associated Polymorphisms.

Tong L, Yu W, Chen L, Selyutin O, Dwyer MP, Nair AG, Mazzola R, Kim JH, Sha D, Yin J, Ruck RT, Davies IW, Hu B, Zhong B, Hao J, Ji T, Zan S, Liu R, Agrawal S, Xia E, Curry S, McMonagle P, Bystol K, Lahser F, Carr D, Rokosz L, Ingravallo P, Chen S, Feng KI, Cartwright M, Asante-Appiah E, Kozlowski JA.

J Med Chem. 2017 Jan 12;60(1):290-306. doi: 10.1021/acs.jmedchem.6b01310. Epub 2016 Nov 15.

17.

Discovery of Chromane Containing Hepatitis C Virus (HCV) NS5A Inhibitors with Improved Potency against Resistance-Associated Variants.

Yu W, Tong L, Hu B, Zhong B, Hao J, Ji T, Zan S, Coburn CA, Selyutin O, Chen L, Rokosz L, Agrawal S, Liu R, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Chen S, Kozlowski JA.

J Med Chem. 2016 Nov 23;59(22):10228-10243. Epub 2016 Nov 9.

PMID:
27792320
18.

Structure-activity relationships of proline modifications around the tetracyclic-indole class of NS5A inhibitors.

Tong L, Yu W, Coburn CA, Chen L, Selyutin O, Zeng Q, Dwyer MP, Nair AG, Shankar BB, Kim SH, Yang DY, Rosenblum SB, Ruck RT, Davies IW, Hu B, Zhong B, Hao J, Ji T, Zan S, Liu R, Agrawal S, Carr D, Curry S, McMonagle P, Bystol K, Lahser F, Ingravallo P, Chen S, Asante-Appiah E, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Nov 1;26(21):5354-5360. doi: 10.1016/j.bmcl.2016.08.097. Epub 2016 Sep 2.

PMID:
27680588
19.

Alternative core development around the tetracyclic indole class of HCV NS5A inhibitors.

Tong L, Yu W, Coburn CA, Meinke PT, Nair AG, Dwyer MP, Chen L, Selyutin O, Rosenblum SB, Jiang Y, Fells J, Hu B, Zhong B, Soll RM, Liu R, Agrawal S, Xia E, Zhai Y, Kong R, Ingravallo P, Nomeir A, Asante-Appiah E, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Oct 15;26(20):5132-5137. doi: 10.1016/j.bmcl.2016.07.057. Epub 2016 Jul 25.

20.

Substituted tetracyclic indole core derivatives of HCV NS5A inhibitor MK-8742.

Yu W, Zhou G, Coburn CA, Zeng Q, Tong L, Dwyer MP, Hu B, Zhong B, Hao J, Ji T, Zan S, Chen L, Mazzola R, Kim JH, Sha D, Selyutin O, Rosenblum SB, Lavey B, Nair AG, Heon Kim S, Keertikar KM, Rokosz L, Agrawal S, Liu R, Xia E, Zhai Y, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Chen S, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Oct 1;26(19):4851-4856. doi: 10.1016/j.bmcl.2016.08.002. Epub 2016 Aug 2.

PMID:
27568086
21.

Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.

Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, Werling K, Kileng H, Koklu S, Gerstoft J, Urbanek P, Flisiak R, Leiva R, Kazenaite E, Prinzing R, Patel S, Qiu J, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Platt HL.

J Hepatol. 2016 Dec;65(6):1112-1119. doi: 10.1016/j.jhep.2016.07.050. Epub 2016 Aug 16.

PMID:
27542322
22.

Matched and mixed cap derivatives in the tetracyclic indole class of HCV NS5A inhibitors.

Dwyer MP, Keertikar KM, Chen L, Tong L, Selyutin O, Nair AG, Yu W, Zhou G, Lavey BJ, Yang DY, Wong M, Kim SH, Coburn CA, Rosenblum SB, Zeng Q, Jiang Y, Shankar BB, Rizvi R, Nomeir AA, Liu R, Agrawal S, Xia E, Kong R, Zhai Y, Ingravallo P, Asante-Appiah E, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Aug 15;26(16):4106-11. doi: 10.1016/j.bmcl.2016.06.063. Epub 2016 Jun 25.

PMID:
27423481
23.

Aryl or heteroaryl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

Yu W, Coburn CA, Nair AG, Wong M, Rosenblum SB, Zhou G, Dwyer MP, Tong L, Hu B, Zhong B, Hao J, Ji T, Zan S, Kim SH, Zeng Q, Selyutin O, Chen L, Masse F, Agrawal S, Liu R, Xia E, Zhai Y, Curry S, McMonagle P, Ingravallo P, Asante-Appiah E, Lin M, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3414-20. doi: 10.1016/j.bmcl.2016.06.056. Epub 2016 Jun 22.

PMID:
27394665
24.

Discovery of potent macrocyclic HCV NS5A inhibitors.

Yu W, Vibulbhan B, Rosenblum SB, Martin GS, Vellekoop AS, Holst CL, Coburn CA, Wong M, Selyutin O, Ji T, Zhong B, Hu B, Chen L, Dwyer MP, Jiang Y, Nair AG, Tong L, Zeng Q, Agrawal S, Carr D, Rokosz L, Liu R, Curry S, McMonagle P, Ingravallo P, Lahser F, Asante-Appiah E, Fells J, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3793-9. doi: 10.1016/j.bmcl.2016.05.042. Epub 2016 May 17.

PMID:
27282743
25.

Alkyl substituted aminal derivatives of HCV NS5A inhibitor MK-8742.

Yu W, Coburn CA, Nair AG, Wong M, Tong L, Dwyer MP, Hu B, Zhong B, Hao J, Yang DY, Selyutin O, Jiang Y, Rosenblum SB, Kim SH, Lavey BJ, Zhou G, Rizvi R, Shankar BB, Zeng Q, Chen L, Agrawal S, Carr D, Rokosz L, Liu R, Curry S, McMonagle P, Ingravallo P, Lahser F, Asante-Appiah E, Nomeir A, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Aug 1;26(15):3800-5. doi: 10.1016/j.bmcl.2016.05.041. Epub 2016 May 14.

PMID:
27282742
26.

Discovery of fused tricyclic core containing HCV NS5A inhibitors with pan-genotype activity.

Yu W, Coburn CA, Yang DY, Meinke PT, Wong M, Rosenblum SB, Chen KX, Njoroge GF, Chen L, Dwyer MP, Jiang Y, Nair AG, Selyutin O, Tong L, Zeng Q, Zhong B, Ji T, Hu B, Agrawal S, Xia E, Zhai Y, Liu R, Kong R, Ingravallo P, Asante-Appiah E, Nomeir A, Fells J, Kozlowski JA.

Bioorg Med Chem Lett. 2016 Jul 1;26(13):3158-3162. doi: 10.1016/j.bmcl.2016.04.084. Epub 2016 Apr 30.

PMID:
27180013
27.

The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.

Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E.

Antimicrob Agents Chemother. 2016 Apr 22;60(5):2954-64. doi: 10.1128/AAC.00051-16. Print 2016 May.

28.

Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors.

McGivern DR, Masaki T, Williford S, Ingravallo P, Feng Z, Lahser F, Asante-Appiah E, Neddermann P, De Francesco R, Howe AY, Lemon SM.

Gastroenterology. 2014 Aug;147(2):453-62.e7. doi: 10.1053/j.gastro.2014.04.021. Epub 2014 Apr 22.

29.

Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.

Côté B, Burch JD, Asante-Appiah E, Bayly C, Bédard L, Blouin M, Campeau LC, Cauchon E, Chan M, Chefson A, Coulombe N, Cromlish W, Debnath S, Deschênes D, Dupont-Gaudet K, Falgueyret JP, Forget R, Gagné S, Gauvreau D, Girardin M, Guiral S, Langlois E, Li CS, Nguyen N, Papp R, Plamondon S, Roy A, Roy S, Seliniotakis R, St-Onge M, Ouellet S, Tawa P, Truchon JF, Vacca J, Wrona M, Yan Y, Ducharme Y.

Bioorg Med Chem Lett. 2014 Feb 1;24(3):917-22. doi: 10.1016/j.bmcl.2013.12.070. Epub 2013 Dec 24.

PMID:
24412110
30.

In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Lai MT, Feng M, Falgueyret JP, Tawa P, Witmer M, DiStefano D, Li Y, Burch J, Sachs N, Lu M, Cauchon E, Campeau LC, Grobler J, Yan Y, Ducharme Y, Côté B, Asante-Appiah E, Hazuda DJ, Miller MD.

Antimicrob Agents Chemother. 2014;58(3):1652-63. doi: 10.1128/AAC.02403-13. Epub 2013 Dec 30.

31.

Systems analysis of eleven rodent disease models reveals an inflammatome signature and key drivers.

Wang IM, Zhang B, Yang X, Zhu J, Stepaniants S, Zhang C, Meng Q, Peters M, He Y, Ni C, Slipetz D, Crackower MA, Houshyar H, Tan CM, Asante-Appiah E, O'Neill G, Luo MJ, Thieringer R, Yuan J, Chiu CS, Lum PY, Lamb J, Boie Y, Wilkinson HA, Schadt EE, Dai H, Roberts C.

Mol Syst Biol. 2012 Jul 17;8:594. doi: 10.1038/msb.2012.24.

32.

Conformation-assisted inhibition of protein-tyrosine phosphatase-1B elicits inhibitor selectivity over T-cell protein-tyrosine phosphatase.

Asante-Appiah E, Patel S, Desponts C, Taylor JM, Lau C, Dufresne C, Therien M, Friesen R, Becker JW, Leblanc Y, Kennedy BP, Scapin G.

J Biol Chem. 2006 Mar 24;281(12):8010-5. Epub 2006 Jan 6.

33.

Residues distant from the active site influence protein-tyrosine phosphatase 1B inhibitor binding.

Montalibet J, Skorey K, McKay D, Scapin G, Asante-Appiah E, Kennedy BP.

J Biol Chem. 2006 Feb 24;281(8):5258-66. Epub 2005 Dec 6.

34.

Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors.

Lau CK, Bayly CI, Gauthier JY, Li CS, Therien M, Asante-Appiah E, Cromlish W, Boie Y, Forghani F, Desmarais S, Wang Q, Skorey K, Waddleton D, Payette P, Ramachandran C, Kennedy BP, Scapin G.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):1043-8.

PMID:
15013020
35.

The development of potent non-peptidic PTP-1B inhibitors.

Dufresne C, Roy P, Wang Z, Asante-Appiah E, Cromlish W, Boie Y, Forghani F, Desmarais S, Wang Q, Skorey K, Waddleton D, Ramachandran C, Kennedy BP, Xu L, Gordon R, Chan CC, Leblanc Y.

Bioorg Med Chem Lett. 2004 Feb 23;14(4):1039-42.

PMID:
15013019
36.

Protein tyrosine phosphatase-1B dephosphorylation of the insulin receptor occurs in a perinuclear endosome compartment in human embryonic kidney 293 cells.

Romsicki Y, Reece M, Gauthier JY, Asante-Appiah E, Kennedy BP.

J Biol Chem. 2004 Mar 26;279(13):12868-75. Epub 2004 Jan 13.

37.

The structural basis for the selectivity of benzotriazole inhibitors of PTP1B.

Scapin G, Patel SB, Becker JW, Wang Q, Desponts C, Waddleton D, Skorey K, Cromlish W, Bayly C, Therien M, Gauthier JY, Li CS, Lau CK, Ramachandran C, Kennedy BP, Asante-Appiah E.

Biochemistry. 2003 Oct 7;42(39):11451-9.

PMID:
14516196
38.

Functional characterization and crystal structure of the C215D mutant of protein-tyrosine phosphatase-1B.

Romsicki Y, Scapin G, Beaulieu-Audy V, Patel S, Becker JW, Kennedy BP, Asante-Appiah E.

J Biol Chem. 2003 Aug 1;278(31):29009-15. Epub 2003 May 13.

39.
40.

Protein tyrosine phosphatases: the quest for negative regulators of insulin action.

Asante-Appiah E, Kennedy BP.

Am J Physiol Endocrinol Metab. 2003 Apr;284(4):E663-70. Review.

41.

The structure of PTP-1B in complex with a peptide inhibitor reveals an alternative binding mode for bisphosphonates.

Asante-Appiah E, Patel S, Dufresne C, Roy P, Wang Q, Patel V, Friesen RW, Ramachandran C, Becker JW, Leblanc Y, Kennedy BP, Scapin G.

Biochemistry. 2002 Jul 23;41(29):9043-51.

PMID:
12119018
42.

The structure of apo protein-tyrosine phosphatase 1B C215S mutant: more than just an S --> O change.

Scapin G, Patel S, Patel V, Kennedy B, Asante-Appiah E.

Protein Sci. 2001 Aug;10(8):1596-605.

43.

The YRD motif is a major determinant of substrate and inhibitor specificity in T-cell protein-tyrosine phosphatase.

Asante-Appiah E, Ball K, Bateman K, Skorey K, Friesen R, Desponts C, Payette P, Bayly C, Zamboni R, Scapin G, Ramachandran C, Kennedy BP.

J Biol Chem. 2001 Jul 13;276(28):26036-43. Epub 2001 May 14.

44.

Divalent cations stimulate preferential recognition of a viral DNA end by HIV-1 integrase.

Yi J, Asante-Appiah E, Skalka AM.

Biochemistry. 1999 Jun 29;38(26):8458-68.

PMID:
10387092
45.

HIV-1 integrase: structural organization, conformational changes, and catalysis.

Asante-Appiah E, Skalka AM.

Adv Virus Res. 1999;52:351-69. Review.

PMID:
10384242
46.

Structural determinants of metal-induced conformational changes in HIV-1 integrase.

Asante-Appiah E, Seeholzer SH, Skalka AM.

J Biol Chem. 1998 Dec 25;273(52):35078-87.

47.

Purification of untagged retroviral integrases by immobilized metal ion affinity chromatography.

Asante-Appiah E, Merkel G, Skalka AM.

Protein Expr Purif. 1998 Feb;12(1):105-10.

PMID:
9473464
48.

Molecular mechanisms in retrovirus DNA integration.

Asante-Appiah E, Skalka AM.

Antiviral Res. 1997 Dec;36(3):139-56. Review.

PMID:
9477115
49.

Gem-dialkyl succinic acids: a novel class of inhibitors for carboxypeptidases.

Asante-Appiah E, Seetharaman J, Sicheri F, Yang DS, Chan WW.

Biochemistry. 1997 Jul 22;36(29):8710-5.

PMID:
9220957
50.

A metal-induced conformational change and activation of HIV-1 integrase.

Asante-Appiah E, Skalka AM.

J Biol Chem. 1997 Jun 27;272(26):16196-205.

Supplemental Content

Loading ...
Support Center